Mar 19, 2024 · Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation RCs. Fusion connects alpha particle emitting isotopes to ...

Mar 19, 2024 · The acquisition brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. It also strengthens ...

Apr 25, 2024 · Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024.

Mar 19, 2024 · Through a subsidiary, AstraZeneca will acquire all of Fusion's outstanding shares for $21 per share in cash at closing, plus a nontransferable contingent value ...

Jan 4, 2024 · Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects ...

Feb 16, 2024 · The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which ...

Mar 19, 2024 · AstraZeneca said on Tuesday it will buy Canadian drug developer Fusion Pharmaceuticals Inc for $2 billion in cash as the Anglo-Swedish drugmaker bets on ...

Dec 27, 2023 · Fusion Pharmaceuticals Inc.'s stock was up by 5.3% in premarket trading on Wednesday, as analysts at two firms talked up its prospects as a takeover target.

Mar 19, 2024 · AstraZeneca will pay an initial $21 a share for Fusion, a premium of more than 97% to Monday's closing price of $10.64 for the Hamilton, Ontario, company.

Mar 19, 2024 · AstraZeneca to acquire Fusion Pharmaceuticals for $2.4 billion, offering $21.00 per share in cash plus a $3.00 CVR, representing a significant premium to ...